Priority index for human genetics and drug discovery

Although human genetics can help identify new drug targets, the best way to prioritize genes as therapeutic targets is uncertain. A new study describes a framework to prioritize potential targets by integrating genome-wide association data with genomic features, disease ontologies and network connectivity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Approaches to prioritize therapeutic targets on the basis of human genetic studies.


  1. 1.

    Plenge, R. M., Scolnick, E. M. & Altshuler, D. Nat. Rev. Drug Discov. 12, 581–594 (2013).

  2. 2.

    Nelson, M. R. et al. Nat. Genet. 47, 856–860 (2015).

  3. 3.

    Fang, H. et al. Nat. Genet. (2019).

  4. 4.

    Rossin, E. J. et al. PLoS Genet. 7, e1001273 (2011).

  5. 5.

    de Lange, K. M. et al. Nat. Genet. 49, 256–261 (2017).

  6. 6.

    Sun, B. B. et al. Nature 558, 73–79 (2018).

  7. 7.

    Raychaudhuri, S. et al. Nat. Genet. 41, 1313–1318 (2009).

  8. 8.

    Okada, Y. et al. Nature 506, 376–381 (2014).

Download references

Author information

Correspondence to Robert M. Plenge.

Ethics declarations

Competing Interests

R.M.P. is a full-time employee at Celgene.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Plenge, R.M. Priority index for human genetics and drug discovery. Nat Genet 51, 1073–1075 (2019).

Download citation

Further reading